1DCCT Research Group. The relationship of a glycemic exposure (HbAlc) to the risk of development and progression of retinopathy in the Diabetes Control and Complieations Trial [J] . Diabetes, 1995, 44: 968-983.
2Stratton I M, Adler A I, Neil H A, et al. Association of glycaemia with macrovascular and micro-vascular complications of type 2 diabetes (UKPDS 35): prospective observational study [J]. BMJ, 2000, 321: 405-412.
3Kilpatrick E S, Rigby A S, Atkin S L. AIC variability and the risk of microvaseular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care [J]. Epub, 2008, 31 (11) : 2198-2202.
4Klein R. Hyperglycemia and mierovascular disease in diabetes [J]. Diabetes Care, 1995, 18: 258-268.
5Brownlee M. Chemistry and molecular cell biology of diabeticcomplications [J]. Nature, 2001, 414: 813-820.
6Brownlee M. The pathobiology of diabetic complications: a unifying mechanism [J]. Diabetes, 2005, 64: 1615-1626.
7Bonora E, Calcaterra F, Lombardi S, et al. Plasma glucose levels throughout the day and HbAlc interrelationships in type 2 diabetes: implicationsfor treatment and monitoring of metabolic control [J] . Diabetes Care, 2001, 24: 2023-2029.
8E1-Kebbi I M, Ziemer D C, Cook C B, et al. Utility of casual postprandial glucose levels in t-ype 2 diabetes management [J] . Diabetes Care, 2004, 27: 335-339.
9American Diabetes Association. Standards of medical care in diabetes [J]. Diabetes Care, 2006, 29 (Suppl 1) : S4-S42,.
10Sacks D B, Bruns D E, Goldstein D E, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (Position Statement)[J]. Diabetes Care, 2002, 25: 750-786.
